Pharmaceutical formulation
AssigneeGlaxo Group Limited
InventorDirk Marinus Johannes Van Schie
Life of this patent
Estimating the term…
Abstract
The present invention provides enteric polymer coated tablet formulations for oral administration which comprise a phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 (Lp-PLA2) inhibitor, processes for preparing such formulations and their use in therapy, in particular the treatment of atherosclerosis.
Claims25
A pharmaceutical formulation comprising a core which includes a pharmaceutically active ingredient which is 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one and a casing which comprises an enteric polymer.
A pharmaceutical formulation comprising:
- (i) a core which comprises:
- a pharmaceutically active ingredient, which is 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl(aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one,
- a disintegrant which is croscarmellose sodium,
- a diluent, which is anhydrous lactose, lactose monohydrate, or a mixture thereof,
- a binder, which is hydroxypropylmethyl cellulose,
- microcrystalline cellulose, and
- a lubricant;
- and
- (ii) a casing which comprises an enteric polymer, an anti-tack agent, and a surfactant.
Dependencies are inferred from the claim text.